共 50 条
- [21] Clofarabine plus cytarabine (ARA-C) combination is active in newly diagnosed patients (pts) ≥ age 50 with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).BLOOD, 2004, 104 (11) : 250A - 250AFaderl, SGandhi, VVerstovsek, SCortes, JRavandi-Kashani, FBeran, MGarcia-Manero, GKoller, CO'Brien, SFerrajoli, AEstrov, ZKwari, MPlunkett, WKantarjian, HM
- [22] Autophagy induction of Acute Myeloid Leukemia (AML) cells after treatment with low dose-cytarabine (Ara-C) and enhanced cytocidal effect on AML cells by combined treatment with ara-c plus lenograstimBLOOD, 2007, 110 (11) : 114B - 114BTang, YongminLi, LixiaWang, DiShen, HongqiangQian, BaiqinLuo, ChunfangZhang, Haizhong
- [23] High Activity of Cladribine (2-CdA) Combined with Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome after Azacitidine FailureBLOOD, 2019, 134Wisniewski, KamilMadry, KrzysztofGrosicki, SebastianMalecki, PiotrPula, BartoszWatek, MarzenaLech-Maranda, EwaTybor, Joanna Gora
- [24] Cross-resistance to cladribine (CdA) and cytarabine (Ara-C) in human etoposide-resistant cell linesANNALS OF ONCOLOGY, 1998, 9 : 147 - 147Albertioni, FLotfi, KWang, YXu, DKnaust, ELillemark, EEriksson, S
- [26] Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemiaAMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (11) : 1711 - 1720Kadia, Tapan M.Ravandi, FarhadMolica, MatteoBataller, AlexBorthakur, GautamDaver, NavalJabbour, EliasDinardo, Courtney D.Pemmaraju, NaveenJain, NitinFerrajoli, AlessandraYlimaz, MusaBose, PrithvirajTidwell, Rebecca SlackMarx, Kayleigh R.Rausch, Caitlin R.Kanagal-Shamanna, RashmiWang, SaIslam, RabiulChamplin, RichardShpall, ElizabethKonopleva, MarinaGarcia-Manero, GuillermoKantarjian, Hagop
- [27] Mylotarg, fludarabine, cytarabine (Ara-C) and cyclosporine (MFAC) combination regimen in patients with CD33-positive primary resistant or relapsed acute myeloid leukemia (AML).BLOOD, 2002, 100 (11) : 339A - 340ATsimberidou, AMEstey, ECortes, JThomas, DGarcia-Manero, GFaderl, SVerstovesk, SO'Brien, SKantarjian, HGiles, F
- [28] Induction Therapy by Ara-C Plus Daunorubicin Versus Ara-C plus Gemtuzumab Ozogamicin: Interim Analysis of a Randomized Phase II Trial of the SAL In Elderly Patients with Acute Myeloid LeukemiaBLOOD, 2010, 116 (21) : 152 - 152Brunnberg, UtaMohr, MichaelNoppeney, RichardDuerk, Heinz A.Sauerland, Maria CristinaMueller-Tidow, CarstenKrug, Utz O.Koschmieder, SteffenKessler, TorstenMesters, Rolf M.Schulz, ChristianeBuchner, ThomasEhninger, GerhardDuehrsen, UlrichServe, HubertBerdel, Wolfgang E.
- [29] Clofarabine and clofarabine plus low-dose cytarabine (ara-C) as induction therapy for patients (pts) ≥ 60 years with newly diagnosed acute myeloid leukemia (AML)BLOOD, 2005, 106 (11) : 786A - 786AFaderl, SRavandi, FFerrajoli, AGarcia-Manero, GEstrov, ZThomas, DAO'Brien, SVerstovsek, SWierda, WCortes, JGiles, FJKwari, MJarmon, RKantarjian, HM
- [30] Combination of Cladribine, Cytarabine and Topotecan (CLAT) for Relapsed or Refractory Acute Myeloid LeukemiaBLOOD, 2015, 126 (23)Chen, XiaomeiWeng, JianyuWang, YulianDeng, ChengxinLuo, ChengweiLiao, PengjunLi, MinmingHuang, XinLai, PeilongHuang, LisiCao, ZhiWan, ChangchunZhong, LiyeWu, SuijingLu, ZeshengZou, XiaoliDu, Xin